Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR

Key Points

• Bank of New York Mellon increased its Monopar Therapeutics stake by 21.2% in the first quarter, holding 78,618 shares worth approximately $4.31 million, or 1.17% of the company.
• MNPR shares opened at $120.21, near their one-year high of $124.82, with a market capitalization of roughly $805 million. The company reported a quarterly loss of $0.46 per share, beating the consensus estimate of a $0.87 loss.
• Analyst sentiment is broadly positive, with an average “Buy” rating and a $112.08 price target, although some firms maintain sell ratings. Institutional investors and hedge funds collectively own only 1.83% of Monopar Therapeutics.

Bank of New York Mellon Corp boosted its holdings in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 21.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,618 shares of the company's stock after buying an additional 13,761 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.17% of Monopar Therapeutics worth $4,307,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Russell Investments Group Ltd. acquired a new position in Monopar Therapeutics in the 3rd quarter valued at approximately $28,000. BNP Paribas Financial Markets lifted its holdings in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company's stock worth $57,000 after buying an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new position in Monopar Therapeutics during the 4th quarter worth about $65,000. JPMorgan Chase & Co. grew its position in shares of Monopar Therapeutics by 1,821.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after buying an additional 1,821 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at about $80,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Price Performance

NASDAQ MNPR opened at $120.21 on Friday. The stock has a market capitalization of $805.41 million, a P/E ratio of -63.27 and a beta of 1.47. The business has a 50 day simple moving average of $89.75 and a 200 day simple moving average of $69.70. Monopar Therapeutics Inc. has a one year low of $29.18 and a one year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.41. Equities analysts expect that Monopar Therapeutics Inc. will post -2.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on MNPR shares. HC Wainwright raised their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday, July 22nd. Wall Street Zen cut Monopar Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, July 12th. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research report on Thursday, July 23rd. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $112.08.

Monopar Therapeutics Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Want to see what other hedge funds are holding MNPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source